Anteris Technologies Global(NASDAQ) AVR

Anteris Technologies Global Corp. makes heart valve systems for people with heart disease. Their main product helps repair narrow heart valves in patients. The company uses special tissue technology to prevent calcium buildup.

High Tech Tools for Heart Health

• DurAVR Heart Valve System: A single-piece heart valve shaped like a human valve to restore normal blood flow; designed to treat aortic stenosis.
• ADAPT Tissue Technology: A proprietary process that treats animal tissue to create bioscaffolds that resist calcium buildup.
• ComASUR Delivery System: A physician-designed, balloon-expandable tool used to place heart valves accurately during medical procedures.
• Regenerative Tissue Products: Sales of specialized tissue bioscaffolds to other medical technology companies for surgical repairs.

Building a Global Clinical Trial

• Commenced recruitment for the global pivotal PARADIGM Trial in Europe in October 2025.
• Received FDA Investigational Device Exemption approval in November 2025 to expand trials into the United States.
• Completed a public offering and a private placement with Medtronic in January 2026, raising gross proceeds of $320.0 million.
• Enrolled and treated the first patients in the United States in May 2026.
• Secured full regulatory clearance from the French National Agency for Medicines and Health Products Safety in June 2026.

Unique Design and Durable Tissue

Anteris uses a biomimetic design that aims to replicate the exact function and flow of a healthy human heart valve. Its proprietary tissue technology has been clinically shown to remain free of calcium for up to 10 years after a procedure.

Checking the Numbers

• Net sales were $1.0 million for the three months ended June 30, 2026, up 63% year over year.
• Research and development expenses reached $40.8 million for the six months ended June 30, 2026, up 24% year over year.
• Selling, general and administrative expenses were $15.3 million for the six months ended June 30, 2026, up 43% year over year.
• Operating loss was $55.0 million for the six months ended June 30, 2026, up 29% year over year.
• Cash, cash equivalents, and restricted cash totaled $260.9 million as of June 30, 2026.

The Bottom Line

Anteris has transitioned from a tissue distributor to a developer of advanced heart valve systems. Its clinical progress and manufacturing expansion support its goal of bringing new cardiac treatments to market.